Interneuron pharmaceuticals Inc., the developer of Redux, said Monday to withdraw the controversial diet drug from the market will take away its primary revenue source and result in a its fourth fiscal quarter, but won't result in immediate job losses or change its operations.
Interneuron loses sole revenue source.